A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma

• Status: Withdrawn
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Diagnosed with hepatocellular cancer

• Discontinued all previous therapies

• At least 18 years of age

Exclusion Criteria:

• Have other treatment options that are potentially curative or effective--such as surgical resection, liver transplant or percutaneous ablation, and/or transcatheter arterial embolization.

• Transplanted liver

• HIV positive

• More than 2 previous systemic chemotherapy treatments